WIPO logo
Mobile | Deutsch | Español | Français | 日本語 | 한국어 | Português | Русский | 中文 | العربية |
PATENTSCOPE

Search International and National Patent Collections
World Intellectual Property Organization
Search
 
Browse
 
Translate
 
Options
 
News
 
Login
 
Help
 
Machine translation
1. (WO2013056087) COMPOSITIONS AND METHODS FOR TREATING AND PREVENTING CORONARY HEART DISEASE
Latest bibliographic data on file with the International Bureau   

Pub. No.:    WO/2013/056087    International Application No.:    PCT/US2012/060014
Publication Date: 18.04.2013 International Filing Date: 12.10.2012
IPC:
G01N 33/53 (2006.01), G01N 33/00 (2006.01)
Applicants: BOSTON HEART DIAGNOSTICS [US/US]; 175 Crossing Boulevard Framingham, MA 01702 (US).
SCHAEFER, Ernst, J. [US/US]; (US) (US only).
POLISECKI, Eliana [US/US]; (US) (US only)
Inventors: SCHAEFER, Ernst, J.; (US).
POLISECKI, Eliana; (US)
Agent: MEYERS, Thomas, C.; Brown Rudnick LLP One Financial Center Boston, MA 02111 (US)
Priority Data:
61/546,802 13.10.2011 US
Title (EN) COMPOSITIONS AND METHODS FOR TREATING AND PREVENTING CORONARY HEART DISEASE
(FR) COMPOSITIONS ET MÉTHODES DE TRAITEMENT ET DE PRÉVENTION D'UNE CORONAROPATHIE
Abstract: front page image
(EN)The invention pertains to a method of determining a statin dosage for an individual in need of treatment with a statin, comprising determining a SLCO1B1 genotype from a nucleic acid sample of the individual, said genotype comprising the presence or absence of the SLCO1B1 -056 polymorphism, and determining an ApoE genotype or phenotype identifying an ApoE polymorphism selected from the group consisting of ApoE2, ApoE3, ApoE4, and any combination thereof, wherein the combination of a SLCO1B1 genotype identifying the presence of the SLCO1B1-056 C polymorphism and the ApoE genotype or phenotype identifying one of the ApoE3/4 or ApoE4/4 genotypes indicates the statin dosage.
(FR)L'invention concerne un procédé de détermination d'un dosage de statine pour un individu ayant besoin d'un traitement par une statine, comprenant la détermination d'un génotype SLCO1B1 à partir d'un échantillon d'acide nucléique de l'individu, ledit génotype comprenant la présence ou l'absence du polymorphisme SLCO1B1-056 et la détermination d'un génotype ou d'un phénotype ApoE identifiant un polymorphisme d'ApoE choisi dans le groupe consistant en ApoE2, ApoE3, ApoE4 et toute combinaison de ceux-ci, la combinaison d'un génotype SLCO1B1 identifiant la présence du polymorphisme SLCO1B1-056 C et le génotype ou phénotype d'ApoE identifiant un des génotypes ApoE3/4 ou ApoE4/4 indique le dosage de statine.
Designated States: AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW.
African Regional Intellectual Property Organization (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, SZ, TZ, UG, ZM, ZW)
Eurasian Patent Organization (AM, AZ, BY, KG, KZ, RU, TJ, TM)
European Patent Office (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR)
African Intellectual Property Organization (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).
Publication Language: English (EN)
Filing Language: English (EN)